The FDA’s focus on data integrity in recent years has proven that it remains an industry issue. The focus has resulted in significantly increased issuance rates of 483 observations, warning letters, and consent decrees. Regulatory agencies, such as the FDA, rely on data to ensure the safety and efficacy of drug products—and this data must be beyond question. Data integrity violations erode public confidence, impugn product quality, and can devastate implicated organizations. Violations undermine the very essence of the FDA’s mission of protecting public safety and can destroy public trust in the regulatory industry.
The data integrity stakes are high and it begs the question: Should not only data integrity principles and requirements, but also training regarding the detection of data integrity breaches within an organization, be a part of routine cGMP training? According to an April 2016 FDA draft guidance document, “Data Integrity and Compliance with cGMP,” the answer is yes. The draft guidance document states:
Training personnel to detect data integrity issues is consistent with the personnel requirements under sections 211.25 and 212.10, which state that personnel must have the education, training, and experience, or any combination thereof, to perform their assigned duties.
Furthermore, senior management, at the local and corporate levels, is responsible for assuring that strict corporate standards, procedures, resources, and communication processes are in place to detect and prevent breaches in data integrity and that such significant issues are identified, escalated, and addressed in a timely manner. So, in addition to staff, senior management must be trained to understand data integrity issues as well.
It is also worth noting that FDA investigators receive specialized training to detect data integrity, data manipulation, and fraud. Objectionable FDA inspection findings may result in the following:
Data integrity nonconformance may occur intentionally and be pervasive in some organizations; however, other organizations’ quality management systems (QMS) may not be designed properly to adopt a data lifecycle approach and be able to control accordingly. Intentional or not, common data integrity issues include, but are not limited to:
To protect itself from data integrity vulnerability, the QMS must include procedures to ensure control of data over its entire lifecycle (the lifecycle consisting of data creation, active data usage, semi-active data usage, and archival). For example, in the data creation phase, an organization needs to be able to answer the following questions:
These questions are but a handful of those that need to be asked. Data integrity auditing should be deployed at the same or greater level (depending on risk) as any other quality system component or subsystem.
ProPharma Group has the experience and expertise to assess and, where applicable, improve your organization’s data integrity-related risk, including ensuring that personnel are effectively trained to detect the presence of data integrity issues.
June 29, 2017
Let’s face it, drug development is a very long process. It is often hard for scientists in a laboratory to picture their drug actually being manufactured at large scale let alone to imagine it in a...
June 29, 2017
So what’s all the hub-bub about Digital Health? Is it really as big as they say? Is it just a fad? Is it all hype? Well, my answer is yes to all of the above. As with all major new technologies and...
June 29, 2017
During the development phase of a new drug, great pains are taken to characterize the molecule and to run a myriad of laboratory and animal tests to determine the product attributes, toxicology...